(Source: Business Wire)
Research and Markets (http://www.researchandmarkets.com/research/bf8447/lebanon_pharmaceut) has announced the addition of the "Lebanon Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
BMI's Lebanon Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Lebanon's pharmaceuticals and healthcare industry.
Lebanon's drug market was estimated to be worth LBP712bn (US$472mn) in 2007. BMI forecasts slow growth, averaging 3.5% year-on-year over the forecast period, with the market reaching just LBP845bn (US$560mn) by the end of 2012. Per capita drug expenditure is relatively high for the country's level of economic development. In 2007, per capita expenditure on prescription and over-the-counter (OTC) medicines came to an estimated US$132 - on a par with richer nations in the Middle East. Indeed, relative to GDP, Lebanon continues to devote a high proportion of GDP to pharmaceuticals, largely as a consequence of strong demand for more expensive, patented drugs.
Political instability is likely to continue to hold back development in a healthcare system that has been severely damaged by conflict. Indeed, only 8% of the population benefit from government-run healthcare.
Key Topics Covered: Executive Summary Lebanon Pharmaceuticals And Healthcare Industry SWOT Political SWOT Economic SWOT Business Environment SWOT Business Environment Ranking Table: Middle East And Africa Pharmaceutical Business Environment Ratings Limits Of Potential Returns Risks To Realisation Of Returns Lebanon - Market Summary Regulatory Regime Public Sector Procurement Intellectual Property Regime USTR 'Special 301' Report 2007 IP Shortcomings Parallel Imports Counterfeit Drugs Table: Losses Due To Counterfeit Drugs In The Middle East, 2007 Free Trade Agreements Pricing And Reimbursement Issues Table: Lebanon's Incremental Drug Margins Industry Developments Health Profile HIV/AIDS Infections Healthcare Sector Hospital Sector Healthcare Sector Reforms Regional Developments Pharmaceuticals Sector Recent Pharmaceutical Industry Developments Research And Development Industry Forecast Scenario Overall Market Forecasts Table: Lebanon's Drug Expenditure Indicators, 2006-2012 Key Growth Factors - Industry Table: Lebanon's Health Expenditure, Estimates And Forecasts, 2006- 2012 Key Growth Factors - Macroeconomic Table: Lebanon - Economic Activity Prescription Market Forecast Table: Lebanon Prescription Market Indicators, 2006-2012 (US$mn unless otherwise stated) OTC Market Forecast Table: Lebanon's OTC Market Indicators, 2006-2012 (US$mn unless otherwise stated) Generics Market Forecast Table: Lebanon's Generics And Patented Market Indicators, 2006-2012 Patented Drug Market Forecast Pharmaceutical Export/Import Market Forecasts Table: Lebanon's Export/Import Indicators, 2006-2012 (US$mn) Other Healthcare Data Forecasts Table: Lebanon - Other Healthcare Data, 2006-2012 Key Risks To BMI Forecasts Competitive Landscape Company Profiles Multinational Companies Pfizer Novartis Merck & Co Johnson & Johnson Sanofi-Aventis Abbott Laboratories Indigenous Companies Chalhoub Pharmaceuticals (CHAPHA) Alfa Laboratories Algorithm Codipha BMI Forecast Modelling How We Generate Our Pharmaceutical Industry Forecasts Pharmaceutical Industry Pharmaceutical Business Environment Ratings Methodology Ratings Overview Table: Pharmaceutical Business Environment Indicators Weighting Table: Weighting Of Components Sources Companies Mentioned: -Pfizer -Novartis -Merck & Co -Johnson & Johnson -Sanofi-Aventis -Abbott Laboratories -Chalhoub Pharmaceuticals (CHAPHA) -Alfa Laboratories -Algorithm -Codipha
For more information visit http://www.researchandmarkets.com/research/bf8447/lebanon_pharmaceut
